<DOC>
	<DOCNO>NCT03075696</DOCNO>
	<brief_summary>This Phase I , multicenter , open-label , dose-escalation study design evaluate safety , tolerability pharmacokinetics ( PK ) novel T-Cell bispecific ( TCB ) , RO7082859 , administer intravenous ( IV ) infusion , follow pretreatment administration one-time , fix dose obinutuzumab . The study divide 3 part : dose escalation ( Parts I II ) dose expansion ( Part III ) . Single-participant dose-escalation cohort use Part I , follow conversion multiple participant dose-escalation cohort ( Part II ) , order define tentative maximum tolerate dose ( MTD ) optimal biological dose ( OBD ) . The expansion cohort ( Part III ) initiate tentative MTD/OBD define , evaluate safety , PK therapeutic activity RO7082859 .</brief_summary>
	<brief_title>A Dose Escalation Study RO7082859 , Administered After Fixed , Single Dose Obinutuzumab Participants With Relapsed/Refractory B-Cell Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Obinutuzumab</mesh_term>
	<criteria>Depending upon study part , history status : 1 ) histologicallyconfirmed hematological malignancy expect express cluster differentiation ( CD ) 20 ; 2 ) relapse failure respond least one prior treatment regimen ; 3 ) available treatment option expect prolong survival ( e.g. , standard chemotherapy autologous stem cell transplant [ SCT ] ) Participant must least one measureable target lesion ( &gt; /=1.5 centimeter [ cm ] ) large dimension computerize tomography [ CT ] scan ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Life expectancy &gt; /=12 week AEs prior anticancer therapy must resolve Grade le equal ( &lt; /= ) 1 Participants must peripheral Bcell count 500 cell per microliter ( cells/mcL ) screen Adequate liver , hematological renal function Negative serologic polymerase chain reaction ( PCR ) test result acute chronic Hepatitis B virus ( HBV ) infection Negative test result Hepatitis C virus ( HCV ) human immunodeficiency virus ( HIV ) Participants chronic lymphocytic leukemia ( CLL ) Participants acute bacterial , viral , fungal infection baseline , confirm positive blood culture within 72 hour prior obinutuzumab infusion Prior treatment systemic immunotherapeutic agent , include , limited , radioimmunoconjugates , antibodydrug conjugate , immune/cytokines monoclonal antibody ( e.g. , anticytotoxic Tlymphocyteassociated protein 4 [ antiCTLA4 ] , antiprogrammed death 1 [ antiPD1 ] antiprogrammed death ligand 1 [ antiPDL1 ] ) within 4 week five halflives drug , whichever short , obinutuzumab infusion Cycle 1 Day 7 Documented refractoriness obinutuzumabcontaining regimen Treatment standard radiotherapy , chemotherapeutic agent , treatment investigational anticancer agent within 4 week prior obinutuzumab infusion Prior solid organ transplantation Prior allogeneic SCT Autologous SCT within 100 day prior obinutuzumab infusion Participant history confirm progressive multifocal leukoencephalopathy ( PML ) Current past history central nervous system ( CNS ) lymphoma Evidence significant , uncontrolled concomitant disease could affect compliance protocol interpretation result , include diabetes mellitus , history relevant pulmonary disorder know autoimmune disease Participants another invasive malignancy last 2 year ( exception basal cell carcinoma tumor deem Investigator low likelihood recurrence ) Administration live , attenuated vaccine within 4 week obinutuzumab infusion anticipation live attenuate vaccine require study Received systemic immunosuppressive medication ( include limit cyclophosphamide , azathioprine , methotrexate , thalidomide , antitumor necrosis factor agent ) exception corticosteroid treatment &lt; /=10 mg/day prednisone equivalent within 2 week prior obinutuzumab infusion Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition would contraindicate use investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>